After more than a year, the fixed increase of covid-19 detection concept stock Maccura Biotechnology Co.Ltd(300463) finally landed, Gaoyi assets were allocated nearly 270 million yuan, and star institutions such as CAITONG fund and Nord fund appeared.
Maccura Biotechnology Co.Ltd(300463) disclosure of fixed increase results
Gao Yi assets, CAITONG fund, etc.
On January 28, Maccura Biotechnology Co.Ltd(300463) disclosed the fixed increase results. The total amount of funds raised by the fixed increase was 1.574 billion yuan, the issuance price was 28.11 yuan / share, the number of shares issued was 56 million, and the lock-in period was 6 months.
Maccura Biotechnology Co.Ltd(300463) the target of this issuance was finally determined to be 17. Specifically, CAITONG fund was allocated 298 million yuan, Nord fund and Xingzheng Global Fund were allocated 84.1988 million yuan and 85.611 million yuan respectively. In addition, 100 billion private placement giant Gao Yi assets were also allocated nearly 270 million yuan.
In fact, as early as the first quarter of 2018, Gaoyi assets invested 130 million yuan and became the ninth largest circulating shareholder of Maccura Biotechnology Co.Ltd(300463) . At that time, the number of shares held was 5203900 shares. However, after continuous adjustment, Gaoyi assets disappeared in the 2018 annual report. In the following years, Gao Yi frequently appeared in the list of the top ten circulating shareholders of Maccura Biotechnology Co.Ltd(300463) .
It is worth noting that on August 7, 2020, Maccura Biotechnology Co.Ltd(300463) issued the proposal on the company’s 2020 stock issuance plan to specific objects and other proposals related to this issuance, which shows that the total amount of funds planned to be raised does not exceed 2.769 billion yuan, nearly half of the difference from the current 1.574 billion yuan.
the raised funds will be invested in the IVD Industrial Park project
Maccura Biotechnology Co.Ltd(300463) previously said that the raised funds will be invested in Maccura Biotechnology Co.Ltd(300463) Tianfu international biological city IVD Industrial Park project, informatization and marketing network construction project and supplementary working capital to expand and strengthen the existing main business of the company.
Maccura Biotechnology Co.Ltd(300463) said that the investment project of raising funds by issuing shares to specific objects is closely related to the company’s main business. The implementation of this raised investment project will effectively alleviate the pressure on the company’s production capacity and expand the company’s business scale; Optimize the company’s production process and improve production efficiency; Improve the company’s R & D and innovation ability and enhance the company’s core competitiveness; At the same time, improve the marketing network and broaden the marketing channels; Improve the information service system and improve the service efficiency; Strengthen the company’s existing main business and expand the company’s asset scale.
The investment project of the raised funds conforms to the national industrial policy and the future development direction of the company, and has good market development prospects and economic benefits. After the issuance, the company will still focus on the R & D, manufacturing and service of in vitro diagnostic reagents and instruments, and the company’s main business scope and business income structure will not change significantly.
After the registration of the newly issued shares was completed, CAITONG fund became the ninth largest shareholder of Maccura Biotechnology Co.Ltd(300463) , and the control right of the company remained unchanged.
covid-19 rapid detection product has obtained EU CE certification
Recently, the crazy rise of Andon Health Co.Ltd(002432) has attracted the attention of many investors. Some investors also asked about the company’s covid-19 self-test products on the interactive platform.
In response, Maccura Biotechnology Co.Ltd(300463) said that New Coronavirus (SARS-Cov-2) IgG/IgM antibody detection kit (colloidal gold method), New Coronavirus antigen detection kit (colloidal gold method) and New Coronavirus neutralization antibody detection kit (colloidal gold method) could be selected for registration of “medical testing” and “household testing”. Different registration systems have different requirements.
At present, the above covid-19 rapid detection products have obtained the EU CE certification (for medical detection), but the “home detection” certification takes a long time. At present, they have obtained the certification of some Asian countries (such as Thailand). The registration certificates of Australia and Europe are still under application, and they are expected to be obtained in about three months; Covid-19 antigen detection and FDA registration are also actively promoted. Because the product registration cycle is long, it is uncertain.
It is understood that the main business of Maccura Biotechnology Co.Ltd(300463) is the independent research and development, production and sales of in vitro diagnostic products and the agent sales of in vitro diagnostic products of foreign well-known brands.
On January 28, Maccura Biotechnology Co.Ltd(300463) also released the performance forecast for 2021. It is expected that the company will realize a net profit of 913 million yuan to 992 million yuan in 2021, with a year-on-year increase of 15% – 25%.
Maccura Biotechnology Co.Ltd(300463) said that during the reporting period, the company accelerated the optimization of independent and agency product structure, focused on increasing the promotion of independent conventional products in China and overseas markets, paid attention to the construction of distribution system, and actively adjusted market strategies to promote the channel competitiveness of the company’s full platform products. During the reporting period, the company’s revenue from independent products maintained a steady growth, and the growth rate and revenue share exceeded that of agency products. Among them, the revenue growth rate of molecular, immune and temporary inspection platform products exceeded 30%; With the increase of R & D investment and de agency, the company’s operating efficiency has been continuously improved. Under the comprehensive influence of multiple factors, the company’s performance in 2021 increased by 15% ~ 25% over the same period of last year.
Founder Securities Co.Ltd(601901) once pointed out that the proportion of independent products in the revenue of Maccura Biotechnology Co.Ltd(300463) in the first half of 2021 increased to 59%, and covid-19 nucleic acid detection products increased by 133% year-on-year. Overseas market is one of the important development areas of the company. Taking advantage of the opportunity of overseas sales of covid-19 testing products, we have actively built overseas sales channels and added more than 130 dealers covering 11 countries and regions. As of the first half of the year, we have established cooperative relations with about 330 overseas dealers, and our products have set foot in more than 100 countries and regions, It has laid a foundation for the export of the company’s independent products.
In terms of share price performance, Maccura Biotechnology Co.Ltd(300463) has experienced two waves of rapid decline, with a cumulative decline of 36.78% last year. The beginning of this year is unfavorable, and it has fallen by 15% in one month. The stock is currently reported at 24.93 yuan, with a total market value of 13.873 billion yuan.
